Urinary Tract Infections in Kidney Transplant Patients Due to *Escherichia coli* and *Klebsiella pneumoniae*-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology

Maria José Espinar¹,², Isabel M. Miranda¹,³, Sofia Costa-de-Oliveira¹,³, Rita Rocha¹, Acácio G. Rodrigues¹,², Cidália Pina-Vaz¹,²,³*

¹ Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal, ² Clinical Pathology Department, Hospital São João, Porto, Portugal, ³ CINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, Porto, Portugal

* cpinavaz@yahoo.com

Abstract

Urinary tract infection (UTI) is a common complication after kidney transplantation, often associated to graft loss and increased healthcare costs. Kidney transplant patients (KTPs) are particularly susceptible to infection by *Enterobacteriaceae*-producing extended-spectrum β-lactamases (ESBLs). A retrospective case-control study was conducted to identify independent risk factors for ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in non-hospitalized KTPs with UTI. Forty-nine patients suffering from UTI by ESBL-producing bacteria (ESBL-P) as case group and the same number of patients with UTI by ESBL-negative (ESBL-N) as control-group were compared. Clinical data, renal function parameters during UTI episodes, UTI recurrence and relapsing rate, as well as risk factors for recurrence, molecular characterization of isolates and the respective antimicrobial susceptibility profile were evaluated. Diabetes mellitus (*p* < 0.007), previous antibiotic prophylaxis (*p* = 0.017) or therapy (*p* < 0.001), previous UTI (*p* = 0.01), relapsing infection (*p* = 0.019) and patients with delayed graft function after transplant (*p* = 0.001) represented risk factors for infection by ESBL positive *Enterobacteriaceae* in KTPs. Interestingly, the period of time between data of transplantation and data of UTI was shorter in case of ESBL-P case-group (28.8 months) compared with ESBL-N control-group (50.9 months). ESBL-producing bacteria exhibited higher resistance to fluoroquinolones (*p* = 0.002), trimethoprim-sulfamethoxazole (*p* < 0.001) and gentamicin (*p* < 0.001). Molecular analysis showed that *bla*<sub>CTX-M</sub> was the most common ESBL encoding gene (65.3%), although in 55.1% of the cases more than one ESBL gene was found. In 29.4% of *K. pneumoniae* isolates, three *bla*-genes (*bla*<sub>CTX-M</sub>-*bla*<sub>TEM</sub>-*bla*<sub>SHV</sub>) were simultaneously detected. Low estimated glomerular filtration rate (*p* = 0.009) was found to be risk factor for UTI recurrence. Over 60% of recurrent UTI episodes were caused by genetically similar strains. UTI by ESBL-producing
Enterobacteriaceae in KTPs represent an important clinical challenge regarding not only hospitalized patients but also concerning outpatients.

**Introduction**

Urinary tract infections (UTI) affect 5 to 36% of kidney transplant patients (KTPs), being the main infectious complication among such patient population [1–4], and one of the most common causes of graft loss and mortality [5,6]. Interestingly, we found a high incidence of extended-spectrum β-lactamases (ESBL) producing bacteria (49%) among KTPs at a large University hospital in Portugal, Centro Hospitalar São João (unpublished data). Usually, infections caused by ESBL-producing bacteria are associated with increased morbidity and mortality which entails enhanced healthcare costs [5,7]. Therefore, UTI caused by ESBL-producing bacteria in KTPs is of extremely clinical relevance.

ESBLs are a large, rapidly evolving group of plasmid-enzymes that confer resistance to penicillins, first-, second-, and third generation cephalosporins, and aztreonam. They are inhibited by beta-lactamase inhibitors such as clavulanic acid [8–10]. During recent years, antibacterial therapy became increasingly more complex. ESBL positive isolates are often associated with multidrug resistance (MDR) especially to fluoroquinolones, aminoglycosides and sulfonamides [11,12]. Insertion sequences, integrons and transposons promiscuously transferred between bacteria played a crucial role in global dissemination of the most common ESBL genes, namely blacTX-M [13]. The prevalence of ESBL-producing organisms increased dramatically in the last decade in particular as an etiological agent in community-acquired infections, health care settings, nursing homes, and even veterinary settings [14–17]. There are several recognized risk factors associated with UTI in KTPs [18–20], however very few studies evaluated selective risk factors for infection by ESBL-producing bacteria in such patients, as well as, its respective molecular epidemiology and antimicrobial susceptibility profiles.

The aim of this study was to identify risk factors, the susceptibility profile and recurrence associated to UTI caused by ESBL-producing *E. coli* and *K. pneumoniae* comparatively to the respective non ESBL-producing counterparts. ESBLs encoding genes were identified. *E. coli* and *K. pneumoniae* isolates sequentially recovered from each patient were genotyped to assess about re-infection or bacterial persistence.

**Materials and Methods**

**Study Design**

This study was approved by Comissão de Etica para a Saúde (CES) do Centro Hospitalar de São João (Approval reference number: 256/13), signed by Prof. Manuel Pestana (Director of Nephrology Department). Patient records/information was anonymized and de-identified prior to analysis.

A retrospective case-control study enrolling 49 outpatients with UTI by *E. coli* and *K. pneumoniae* ESBL-producing bacteria (ESBL-P), as case-group, and 49 outpatients with UTI by the same species but ESBL negative (ESBL-N), as a control-group, was performed. All patients were kidney transplant patients (KTPs) from Centro Hospitalar São João, Porto (Portugal) with documented UTI between January 2012 and August 2012.
Variables

Demographic data (age, gender) and clinical variables such as delayed graft function, bacteremia, fungemia, previous urinary tract infection, creatinine blood level (reference range 0.6–1.1 mg/dL), and the percentage of patients with low estimated glomerular filtration rate (eGFR) during UTI (<60 mL/min/1.73m²) was registered [21]; eGFR was calculated using a MDRD (Modification of Diet in Renal Disease) study equation [22] during UTI. Additional data such as leukocyturia, erythrocyturia, urinary nitrites, immunosuppression therapeutic regimen, antibiotic prophylaxis, antibiotic therapy (comprising the two previous months) was recorded. Patient comorbidities such as hypertension, coronary disease and diabetes mellitus (either preexistent or post-transplantation), Cytomegalovirus (CMV) infection, percentage of graft loss and mortality, along a 3 months period, were also registered. It was calculated, in months, the period between post-transplant data and this UTI episode. A comparison of antimicrobial susceptibility profile between case-group (ESBL-P) and control-group isolates (ESBL-N), as well as, between successive isolates from the same patient was also performed. Recurrent UTI was defined as two episodes separated at least 1 month, during the following three months. Relapsing UTI was defined as two episodes caused by the same species with an identical antibiogram after appropriate treatment [23]. The percentage and risk factors for recurrence were calculated for both groups.

Phenotype characterization and Molecular analysis of clinical isolates

Eighty-two isolates of ESBL-producing E. coli (n = 50) and K. pneumoniae (n = 32) were recovered from 49 KTPs (case-group); 25 patients yielded each a single isolate, 16 patients two isolates each, 7 patients three isolates each, one single patient yielding four isolates. Forty-nine ESBL negative isolates (32 E. coli and 17 K. pneumoniae) were recovered from the 49 patients of control group. All isolates were analyzed by Vitek2 System (BioMérieux, Marcy L’Etoile, France) using GN card for identification and the AST-60 for antimicrobial susceptibility profile. ESBL presence was confirmed by disc diffusion method, according to the recommendations of Clinical Laboratory Standard Institute [24]; a double-disk synergy test with cefotaxime (30 μg) and ceftazidime (30 μg) alone and in combination with clavulanic acid (10 μg) (Oxoid, Hampshire, U.K.) was performed in Mueller-Hinton agar. Quality control of susceptibility tests was carried out using Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC700603 type strains, as recommended by CLSI protocol [24] and plasmid DNA was extracted using the NZY Miniprep Kit (NZYTech, Lisbon, Portugal). Genomic DNA was extracted according the "boiling method". DNA quantification and quality was assessed in a Nanodrop 2000c equipment (Thermo Fisher Scientific, CA, U.S.). Plasmid and genomic DNA were visualized in a Molecular Imager ChemiDoc XRS (BioRad, CA, U.S.) after electrophoresis (80 V, 1 hour) in a 0.8% agarose gel.

The most frequently ESBL genes (bla_{CTX-M}, bla_{TEM}, and bla_{SHV}) were screened by PCR multiplex, as previously described [25]. The primers used were: bla_{SHV}: 5’-ATCCACTATCCGCAGG-3’ and 5’-TCATTCCGTTCCCTCAG-3’; bla_{TEM}: 5’-GAGTTATTCACCATTTCCGCCAG-3’ and 5’-GGCGGAAAATCTCTCAAGGATC-3’; bla_{CTX-M}: 5’-GTTGTTAGGAAAGTGCCGCC-3’ and 5’-GCCCGAGGTGAAGTGGATC-3’. Primers amplified the internal fragments of ESBLs genes possessing different sizes. Multiplex PCR was performed in a 25 μl reaction mixture containing 1x Dream Taq buffer (Fermentas), 2.5 mM MgCl₂, 10 mM dNTPs, 2.5–40 pmol of specific-group primers, 50–150 ng plasmid DNA and 1 U of Dream Taq Polymerase (Fermentas). Amplification reactions were carried out in Mastercycler Realplex² (Eppendorf) under the following conditions: initial denaturation at 95°C for 2 min, followed by 30 cycles of denaturation (95°C for 30 sec), annealing (59°C for 30 sec), extension
(72°C for 30 sec) and a final extension step (72°C for 10 min). PCR products were run at 80 V, during 1 hour in a 2.5% agarose gel containing 0.002% Ethidium Bromide (AppliChem, Darmstadt, Germany). ESBLs bacteria exhibiting well-characterized ESBL genes kindly gift by Dr. Rafael Cantón (Servicio de Microbiología, Hospital Universitario Ramón y Cajal) were used as positive controls.

Sequential isolates from case-group (ESBL-P)- 2 or more isolates (24 patients)—were genotyped by RAPD. Distinct primers were used for *E. coli* [26] (GTGATCGCAG) and *K. pneumoniae* [27] (ACGTATCTGC) isolates. Each reaction contained: 1x DreamTaq buffer (Fermentas, Thermo Fisher Scientific, CA, U.S.), 0.2 mM of dNTPs, 0.5 pmol of primer, 14 mM of dimethylsulfoxide (Merck, NJ, U.S.), 10 ng of genomic DNA and 0.6 U of DreamTaq polymerase (Fermentas). PCR protocol was performed in a Mastercycler Realplex² thermocycler (Eppendorf, Wesseling-Berzdorf, Germany), and involved the following steps: initial denaturation at 94°C for 1 min, followed by 45 cycles of denaturation (94°C at 1 min), annealing (34°C at 1 min), extension (72°C at 2 min), and a final extension step (72°C at 10 min). PCR products were separated by electrophoresis (60 V for 3 hours) in a 2.5% agarose gel. DNA fingerprints were compared by visual inspection with the Molecular Imager ChemiDoc XRS (BioRad). Clonality was assessed by visual inspection of the different fragments obtained, in a range of 2000–200 bp for *E. coli* and 3000–250 bp for *K. pneumoniae*. According to Wong et al. [28], isolates displaying identical RAPD profiles or showing 3 minor band variations were considered the same strain.

Statistical analysis

Statistical analysis was performed using IBM SPSS statistical package (Chicago, IL) version 20. Continuous variables were summarized as mean value and standard deviation (SD). Categorical variables, summarized as percentages, were compared using Chi-square test (or Fishers’ exact test whenever was necessary) and Student’s *t*- test. Multivariable logistic regression analysis, using a likelihood ratio-based backward exclusion method, was used to evaluate independent risk factors associated with ESBL positive UTI. A two-sided *p*<0.05 value was considered to be statistically significant.

Results

Clinical data and risk factors

Patient clinical data, including demographic characteristics, co-morbidities, clinical laboratory data, immunosuppressive therapeutic regimen, previous UTI and antibiotic exposure are summarized in Table 1. The number of patients with diabetes mellitus, with low eGFR, under antibiotic (prophylaxis or therapy), with history of previous UTI, relapsing UTI, and delayed graft function were significantly higher in the ESBL-P group; the mean period of time between data of transplantation and UTI episode was shorter in case of ESBL-P case group (Table 1).

Regarding immunosuppression, all patients showed adequate therapeutic levels; mean values were: 8.1 ng/mL for tacrolimus, 190.5 ng/mL for cyclosporine and 6.28 ng/mL for everolimus. Patient death occurred solely among ESBL-P group, during the 3 months after infection (Table 1). No bacteremia or fungemia, urinary tract obstruction or graft loss was found among both patients groups. UTI recurrence frequency, up to 46.9%, was similar in both groups (Table 1). The analysis of the risk factors associated to UTI by ESBL-positive bacteria revealed that diabetes mellitus, antibiotic prophylaxis, antibiotic therapy during the previous 2 months, previous UTI, relapsing UTI and delayed graft function contributed independently (Table 1). Prophylactic antibiotic therapy was more often used in ESBL-P group; it consisted of oral trimethoprim/sulfamethoxazole during at least 12 months. Antibiotic therapy, during the two
months previous to UTI, involved mainly trimethoprim-sulfamethoxazole (48.9%), ceftriaxone (21.3%) and piperacilina-tazobactam (17.1%) therapeutics. During UTI episode, amoxicillin associated to clavulanic acid was frequently administrated or alternatively in case of an ESBL positive isolate, a carbapenem for a 10 day period.  

Table 1. Comparative analysis of clinical and laboratorial data from kidney transplant patients yielding extended spectrum β-lactamase positive (ESBL-P) and extended spectrum β-lactamase negative (ESBL-N) Escherichia coli and Klebsiella pneumoniae isolated from urine. Predicted risk factors were obtained after univariate and multivariate (logistic regression) analyses.

|                                | ESBL Positive Case-group | ESBL Negative Control-group | p     | OR* | OR*adjusted | CI 95%  | ** | p   |
|--------------------------------|--------------------------|----------------------------|-------|-----|-------------|---------|----|-----|
| Number of patients             | 49                       | 49                         |       |     |             |         |    |     |
| Male gender                    | 17 (34.7%)               | 18 (36.7%)                 |       |     |             |         |    |     |
| Mean age (SD)                  | 53.8 (14.8)              | 51.6 (13.5)                |       |     |             |         |    |     |
| Comorbidities                  |                          |                            |       |     |             |         |    |     |
| Diabetes mellitus              | 20 (40.8%)               | 8 (16.3%)                  | 0.007 | 3.53| 6.81        | 1.75–26.39| 0.006|
| Hypertension                   | 32 (65.3%)               | 32 (65.3%)                 | NS    | -   | -           | -       |    |     |
| Coronary disease               | 11 (20.4%)               | 11 (24.5%)                 | NS    | -   | -           | -       |    |     |
| Cytomegalovirus Infection      | 2 (4.1%)                 | 2 (4.1%)                   | NS    | -   | -           | -       |    |     |
| Urinary Nitritus               | 6 (12.5%)                | 13 (26.5%)                 | NS    | -   | -           | -       |    |     |
| Eritrocyturia (mean value)     | 120.6μL                  | 358.7μL                    | NS    | -   | -           | -       |    |     |
| Leucocyturia (mean value)      | 333.0μL                  | 243.2μL                    | NS    | -   | -           | -       |    |     |
| Low eGFR during UTI**          | 39 (79.6%)               | 28 (57.1%)                 | 0.017 | 1.4 | -           | -       |    |     |
| Immunosupression Regimen       |                          |                            |       |     |             |         |    |     |
| Tacrolimus                     | 26 (53%)                 | 23 (46.9%)                 | NS    | -   | -           | -       |    |     |
| Ciclosporine                   | 18 (36.7%)               | 22 (44.9%)                 | NS    | -   | -           | -       |    |     |
| Everolimus                     | 2 (4.1%)                 | 4 (8.2%)                   | NS    | -   | -           | -       |    |     |
| Antibiotic prophylaxis         | 24 (49%)                 | 14 (28.6%)                 | 0.038 | 2.40| 3.73        | 1.09–12.78| 0.036|
| Previous antibiotic therapy    | 34 (69.4%)               | 13 (26.5%)                 | <0.001| 6.27| 15.8        | 4.28–58.5 | 0.000|
| Previous UTI                   | 39 (79.6%)               | 28 (57.1%)                 | 0.01  | 4.92| 7.73        | 1.90–31.36| 0.004|
| Recurrence UTI                 | 23 (46.9%)               | 20 (40.8%)                 | NS    | -   | -           | -       |    |     |
| Relapsing UTI                  | 22 (44.9%)               | 11 (22.4%)                 | 0.019 | 2.81| 3.42        | 1.00–11.66| 0.049|
| Delayed graft function         | 27 (62.8%)               | 11 (27.5%)                 | 0.001 | 4.44| 4.1         | 1.25–13.61| 0.020|
| Mortality                      | 2 (4%)                   | 0 (0%)                     | NS    | -   | -           | -       |    |     |
| Mean period of time between data of transplantation and UTI (months) | 28.8 | 50.9 | 0.011 | - | - | - |     |     |

UTI = Urinary tract infection; NS = not significant; 
**Low eGFR = <60 ml/min/1.73m²; 
Mortality in the next 3 months after infection; 
*Odds Ratio; 
** Confident interval at 95%; 
~15 patients without data.
Antimicrobial susceptibility profile

The comparative analysis of the antimicrobial susceptibility profiles showed statistically significant differences between isolates from ESBL-P and ESBL-N groups, in what concerns fluoroquinolones, trimethoprim-sulfamethoxazole and aminoglycosides. No significantly differences were seen regarding K. pneumoniae susceptibility to amikacin between both study groups (Table 2). No resistance to carbapenems was found in both groups.

Molecular characterization of ESBL genes

ESBL genes (blaCTX-M, blaSHV, and blaTEM group) were detected by PCR multiplex in isolates from ESBL-P group (Table 3). Interestingly, sequential isolates recovered from the same patient express the same ESBL genes. The gene most frequently expressed was blaCTX-M (65.3%), either alone (18.4%) or in combination with another ESBL gene (46.9%), followed by blaTEM (61.2%) and blaSHV (40.8%). More than half of the case- group express more than one ESBL gene, being the association blaCTX-M-blaTEM the most frequent (28.5%), particularly among E. coli strains (37.5%). Among K. pneumoniae isolates, blaCTX-M-blaTEM-blaSHV (29.4%) was the most frequent association, followed by blaCTX-M-blaSHV (23.5%). Strains expressing a single ESBL gene, blaCTX-M (25%) and blaTEM (18.8%) corresponded most often to E. coli, while blaSHV was more common among K. pneumoniae isolates (17.6%) (Table 3). No correlation was found between ESBL genotype and parameters such as: antimicrobial resistance, clinical variables such as diabetes mellitus, previous antibiotic prophylaxis/treatment and UTI recurrence.

Recurrence of ESBL-P strains

Although the level of recurrence found for both groups was similar (around 40%), the relapsing percentage was significantly higher on control-group (Table 1). The 48 ESBL-P isolates recovered from 24 patients with recurrent UTI (over 60%) showed similar antimicrobial susceptibility profiles (relapsing cases) and similar RAPD patterns (61.5% in the case of E. coli and 63.6% in the case of K. pneumoniae) (see representative examples in Fig 1). Conversely, isolates from 37.5% of the patients with recurrent UTI exhibited distinct RAPD patterns (see representative examples in Fig 1); such recurrent isolates exhibited invariably increased antimicrobial resistance, in particular to gentamicin and quinolones (data not shown). Comparative analysis of patients with and without UTI recurrence revealed that low eGFR was risk factor for recurrence (Table 4).

Discussion

Kidney transplant recipients display many risk factors for UTI and are considered a particular vulnerable population to such infections [1]. Several studies have evaluated risk factors for UTI in community infections [11,18,29] and health care settings [20,30,31]. The high incidence of ESBL positive infections among KTPs with diabetes mellitus, as well as, in patients who received previous antimicrobial therapy were also reported by several authors [19,20]. Most of those studies report to hospitalized patients being the outpatient studies much more scarce. Similar to Linares study [19] impairment of renal function, measured by delayed graft function, was risk factor for UTI due to ESBL-positive bacteria. The significant reduction of eGFR during UTI among KTPs [18] and high creatinine values [32] had already been reported by previous authors [18]. However, we demonstrated that such reduction is significantly higher among patients with UTI caused by ESBL-P bacteria probably due to the existence of acute kidney injury because of delayed graft function. For the first time, patients with low eGFR showed
Table 2. Comparative analysis of the distribution of antimicrobial resistant extended spectrum β-lactamase positive (ESBL-P) and extended spectrum β-lactamase negative (ESBL-N) isolates (n/%) recovered from urinary tract infection of kidney transplant patients.

| ESBL Positive Case-group | ESBL NegativeControl-group | p     |
|--------------------------|---------------------------|-------|
| *E. coli*- Resistance to  |                           |       |
| Ciprofloxacin            | 16 / 48.5%                | 5 / 15.6% | 0.004 |
| Levofloxacin             | 16 / 48.5%                | 5 / 15.6% | 0.002 |
| Norfloxacin              | 12 / 36.4%                | 6 / 18.8% | <0.001|
| Cotrimoxazol             | 26 / 78.8%                | 19 / 59.4% | 0.036 |
| Gentamicin               | 8 / 24.2%                 | 2 / 6.2%  | 0.044 |
| Amikacin                 | 5 / 15.2%                 | 0 / 0%    | 0.022 |
| *K. pneumoniae*-Resistance to |                       |       |
| Ciprofloxacin            | 6 / 37.5%                 | 4 / 22.5% | 0.028 |
| Levofloxacin             | 6 / 37.5%                 | 0 / 0%    | 0.020 |
| Norfloxacin              | 6 / 37.5%                 | 3 / 17.6% | 0.004 |
| Cotrimoxazol             | 15 / 93.8%                | 9 / 47.1% | 0.002 |
| Gentamicin               | 9 / 56.2%                 | 1 / 5.9%  | 0.002 |
| Amikacin                 | 4 / 25.0%                 | 3 / 17.6% | NS    |
| Total strains- Resistance to |                          |       |
| Ciprofloxacin            | 22 / 44.9%                | 9 / 18.4% | 0.002 |
| Levofloxacin             | 22 / 44.9%                | 5 / 10.2% | <0.001|
| Norfloxacin              | 18 / 36.7%                | 9 / 18.4% | <0.001|
| Cotrimoxazol             | 41 / 83.7%                | 34 / 55.1% | <0.001|
| Gentamicin               | 16 / 32.7%                | 2 / 4.1%  | 0.002 |
| Amikacin                 | 2 / 4.1%                  | 0 / 0%    | NS    |

NS = not significant

doi:10.1371/journal.pone.0134737.t002

Table 3. Extended spectrum β-lactamase (ESBL) genotypes of *Escherichia coli* and *Klebsiella pneumoniae* isolates from urine of kidney transplant patients.

| ESBL genes | *E.coli* = 32 (%) | *K.pneumoniae* = 17 (%) | Total strains = 49 (%) |
|------------|-------------------|-------------------------|------------------------|
| Single ESBL gene |                     |                         |                        |
| *bla* CTX-M   | 8 (25%)           | 1 (5.9%)                | 9 (18.4%)              |
| *bla* TEM     | 6 (18.8%)         | 3 (17.6%)               | 9 (18.4%)              |
| *bla* SHV     | 3 (9.4%)          | 3 (17.6%)               | 6 (12.4%)              |
|               |                   |                         | 24 (48.9%)             |
| Two or more ESBL genes |                   |                         |                        |
| *bla* CTX-M + *bla* TEM | 12 (37.5%) | 2 (11.8%)                | 14 (28.5%)            |
| *bla* CTX-M + *bla* SHV | 0 (0%)          | 4 (23.5%)               | 4 (8.2%)               |
| *bla* TEM + *bla* SHV | 2 (6.3%)        | 2 (11.8%)               | 4 (8.2%)               |
| *bla* CTX-M + *bla* SHV + *bla* TEM | 1 (3.1%) | 5 (29.4%)                | 6 (12.2%)              |
|               |                   |                         | 28 (57.1%)             |
| Overall genes |                     |                         |                        |
| *bla* CTX-M   | 21 (65.6%)        | 11 (64.7%)              | 32 (65.3%)             |
| *bla* TEM     | 21 (65.6%)        | 9 (52.9%)               | 30 (61.2%)             |
| *bla* SHV     | 6 (18.7%)         | 14 (82.3%)              | 20 (40.8%)             |

doi:10.1371/journal.pone.0134737.t003
Fig 1. Recurrent UTIs are caused by clonal ESBL producing bacteria. Representative example of RAPD patterns of 6 strains of extended spectrum β-lactamase positive *Escherichia coli* (left panel; patients A, B, C) and 6 strains of extended spectrum β-lactamase positive *Klebsiella pneumoniae* (right panel; patients D, E, F); (1) represents strains recovered from the first urinary tract infection episode and (2) represents the second isolate recovered from the same patient. M- DNA Ladder 100 bp (Fermentas).

doi:10.1371/journal.pone.0134737.g001

Table 4. Comparative analysis between clinical and laboratorial data of kidney transplant patients with urinary tract infection recurrence; molecular characterization of ESBL *Escherichia coli* and *Klebsiella pneumoniae* isolates.

|                                | Patients with UTI recurrence | Patients without UTI recurrence | p      | OR* | CI 95% ** |
|--------------------------------|-----------------------------|--------------------------------|-------|-----|-----------|
| Number of patients             | 43                          | 55                             |       |     |           |
| Diabetes mellitus              | 14 (32.6%)                  | 14 (25.5%)                     | NS    | -   | -         |
| Hypertension                   | 31 (72.1%)                  | 33 (60.0%)                     | NS    | -   | -         |
| Coronary disease               | 10 (23.3%)                  | 12 (21.8%)                     | NS    | -   | -         |
| Low eGFR during UTI**          | 35 (81.4%)                  | 31 (56.4%)                     | 0.009 | 0.295| 0.116–0.752|
| Urinary Nitrites               | 9 (20.9%)                   | 11 (20.5%)                     | NS    | -   | -         |
| Antibiotic prophylaxis         | 15 (34.9%)                  | 23 (41.8%)                     | NS    | -   | -         |
| Previous antibiotic therapy    | 22 (51.2%)                  | 25 (46.5%)                     | NS    | -   | -         |
| Previous UTI                   | 30 (69.8%)                  | 37 (67.3%)                     | NS    | -   | -         |
|bla genes                       | 23 (53.5%)                  | 26 (47.3%)                     | NS    | -   | -         |

UTI = Urinary tract infection;
**Low eGFR = <60 ml/min/1.73m²;
*Odds Ratio;
** Confident interval at 95%

doi:10.1371/journal.pone.0134737.t004
a risk factor for UTI recurrence, fact not found in Wu et al. study [29]. Remarkably, the period of time between data of transplant and the instauration of UTI episode by ESBL-P bacteria was shorter than ESBL-N group. This fact it could be due to delayed graft function which may will predispose infection by bacteria. On other hand, antibiotic (prophylaxis or therapeutic) can induce the acquisition of antibiotic resistance genes predisposing to ESBL-P bacteria infection. PCR multiplex of the three most prevalent ESBLs genes (\textit{bla}_{\text{CTX-M}}, \textit{bla}_{\text{TEM}}, \textit{and bla}_{\text{SHV}}) in \textit{E. coli} and \textit{K. pneumoniae} revealed that \textit{bla}_{\text{CTX-M}} was the most common ESBL gene. A higher predominance of \textit{bla}_{\text{CTX-M}} enzyme among ESBL positive \textit{E. coli} was reported in Greece [33]. Conversely, extremely variable rates among different centres (1.2 to 49.5%) were described in Italy [34]. In Portugal, national surveys are not available. Nevertheless, studies from individual hospitals reflect a common spread of \textit{bla}_{\text{CTX-M}} and \textit{bla}_{\text{TEM}} [35,36]. Reports describing the co-production of different ESBLs by clinical isolates are increasing among European countries [37]. A high prevalence of \textit{E. coli} and \textit{K. pneumoniae} (57.3%) isolates exhibiting two or three genes was previously reported [38], similar to our study. Organisms producing \textit{bla}_{\text{SHV}} and \textit{bla}_{\text{TEM}} types of ESBLs have traditionally been responsible for serious health care related infections [39] while \textit{bla}_{\text{CTX-M}} types have been mainly associated with community-onset UTI [40]. The epidemiology of ESBL-producing bacteria is becoming more complex and the limits between hospital and community settings are narrowing [15], being this fact particularly true in the case of KTPs. Such out-patients are frequently admitted to hospital. Thus, microorganism origin may not be obvious since patients can acquired an ESBL positive strain during the last hospital admission, and just after discharge a subsequent UTI can manifest. While other studies found a correlation between \textit{bla}_{\text{CTX-M}}-producing bacteria and resistance to fluoroquinolones [11] such correlation was not found in our study population. Regarding RAPD similar patterns corresponded to identical antimicrobial susceptibility profiles, while different RAPD patterns correspond to distinct profiles. Interestingly, recurrent isolates with different RAPD patterns showed invariably higher antimicrobial resistance, suggesting a complex, yet unveiled concomitance of multiple mechanism of resistance.

In conclusion, we have demonstrated that delayed graft function, diabetes mellitus, previous antibiotic exposure, antibiotic prophylaxis and relapsing UTI are independent risks factors for acquiring infections by ESBL-producing \textit{E. coli} and \textit{K. pneumoniae}. Molecular epidemiology showed that \textit{bla}_{\text{CTX-M}} was the most common ESBL encoding gene, either alone or in association with other genes. Low eGFR and high blood creatinine are risk factors for UTI recurrence. The high co-resistance to other antibiotics (non-\beta-lactams) found from ESBL producing bacteria in UTI from KTPs, remains a serious clinical challenge.

Acknowledgments
The authors would like to thank Isabel Santos for the excellent technical assistance.

Author Contributions
Conceived and designed the experiments: MJE CPV. Performed the experiments: MJE IMM RR. Analyzed the data: MJE SCO. Contributed reagents/materials/analysis tools: MJE IMM CPV AGR. Wrote the paper: MJE IMM SCO CPV.

References
1. de Souza RM, Olsburgh J (2008) Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 4: 252–264. doi: 10.1038/ncpneph0781 PMID: 18334970
2. Ariza-Heredia EJ, Beam EN, Lesnick TG, Kremers WK, Cosio FG, et al. (2013) Urinary tract infections in kidney transplant recipients: role of gender, urologic abnormalities, and antimicrobial prophylaxis. Ann Transplant 18: 195–204. doi: 10.12659/AOT.883901 PMID: 23792521
3. Vidal E, Torre-Cisneros J, Blanes M, Montejo M, Cervera C, et al. (2012) Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis 14: 595–603. doi: 10.1111/j.1399-3062.2012.00744.x PMID: 22650416

4. Pinheiro HS, Mituassu AM, Carminatti M, Braga AM, Bastos MG (2010) Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients. Transplant Proc 42: 486–487. doi: 10.1016/j.transproceed.2010.02.002 PMID: 20304172

5. Abbott KC, Swanson SJ, Richter ER, Bohen EM, Agodoa LY, et al. (2004) Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 44: 353–362. PMID: 15264195

6. Mitra S, Alangaden GJ (2011) Recurrent urinary tract infections in kidney transplant recipients. Curr Infect Dis Rep 13: 579–587. doi: 10.1007/s11908-011-0210-z PMID: 21870039

7. Tumbarello M, Sanguinetti M, Montuori E, Trezarichi EM, Posteraro B, et al. (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51: 1987–1994. PMID: 17387156

8. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18: 657–686. PMID: 16223952

9. Livermore DM (1995) beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8: 557–584. PMID: 8665470

10. Bush K, Fisher JF (2011) Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gram-negative bacteria. Annu Rev Microbiol 65: 455–478. doi: 10.1146/annurev-micro-090110-102911 PMID: 21740228

11. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniaín MA, et al. (2004) Epidemiological and clinical features of infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42: 1089–1094. PMID: 15004058

12. Bonnet R (2004) Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48: 1–14. PMID: 14693512

13. Carattoli A (2013) Plasmids and the spread of resistance. Int J Med Microbiol 303: 298–304. doi: 10.1016/j.ijmm.2013.02.001 PMID: 23499304

14. Dhanji H, Doumith M, Rooney PJ, O'Leary MC, Loughrey AC, et al. (2011) Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK. J Antimicrob Chemother 66: 297–303. doi: 10.1093/jac/dkg463 PMID: 21131323

15. Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56: 52–59. PMID: 15917288

16. Bagattini M, Crivaro V, Di Popolo A, Gentile F, Scarcella A, et al. (2006) Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. J Antimicrob Chemother 57: 979–982. PMID: 16531430

17. D'Andrea MM, Arena F, Pallecchi L, Rossolini GM (2013) CTX-M-type beta-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 303: 305–317. doi: 10.1016/j.ijmm.2013.02.008 PMID: 23490927

18. Lim JH, Cho JH, Lee JH, Park YJ, Jin S, et al. (2013) Risk factors for recurrent urinary tract infection in kidney transplant recipients. Transplant Proc 45: 1584–1589. doi: 10.1016/j.transproceed.2012.12.011 PMID: 23726625

19. Linares L, Cervera C, Cofan F, Lizaso D, Marco F, et al. (2008) Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. Am J Transplant 8: 1000–1005. PMID: 18727176

20. Lautenbach E, Patel JB, Bilker WB, Edelman PH, Fishman NO (2001) Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32: 1162–1171. PMID: 11283805

21. Levey AS, Levin A, Kellum JA (2013) Definition and classification of kidney diseases. Am J Kidney Dis 61: 686–688. doi: 10.1053/j.ajkd.2013.03.003 PMID: 23582249

22. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YT, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254. PMID: 16908915

23. Bodro M, Sanclemente G, Lipperheide I, Allali M, Marco F, et al. (2015) Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients. Am J Transplant 15: 1021–1027. doi: 10.1111/ajt.13075 PMID: 25676738
24. CLSI (2011) Performance standards for antimicrobial susceptibility testing; 21st informational supplement. M100–S21.

25. Espinar MJ, Rocha R, Ribeiro M, Goncalves Rodrigues A, Pina-Vaz C (2011) Extended-spectrum beta-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system. J Med Microbiol 60: 756–760. doi: 10.1099/jmm.0.024075-0 PMID: 21330411

26. Nowrouzian F, Hesselmar B, Saalman R, Strannegard IL, Aberg N, et al. (2003) Escherichia coli in infants' intestinal microflora: colonization rate, strain turnover, and virulence gene carriage. Pediatr Res 54: 8–14. PMID: 12700366

27. Eisen D, Russell EG, Tymms M, Roper EJ, Grayson ML, et al. (1995) Random amplified polymorphic DNA and plasmid analyses used in investigation of an outbreak of multiresistant Klebsiella pneumoniae. J Clin Microbiol 33: 713–717. PMID: 7751382

28. Wong NA, Linton CJ, Jalal H, Millar MR (1994) Randomly amplified polymorphic DNA typing: a useful tool for rapid epidemiological typing of Klebsiella pneumoniae. Epidemiol Infect 113: 445–454. PMID: 7995354

29. Wu SW, Liu KS, Lin CK, Hung TW, Tsai HC, et al. (2013) Community-acquired urinary tract infection in kidney transplantation: risk factors for bacteremia and recurrent infection. J Formos Med Assoc 112: 138–143. doi: 10.1016/j.jfma.2012.01.010 PMID: 23473526

30. Rodriguez-Bano J, Picon E, Gion P, Hernandez JR, Cisneros JM, et al. (2010) Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 48: 1726–1731. doi: 10.1128/JCM.02353-09 PMID: 20181897

31. Lucet JC, Chevret S, Decre D, Vanjak D, Macrez A, et al. (1996) Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 22: 430–436. PMID: 8852958

32. Ramadas P, Rajendran PP, Krishnan P, Alex A, Siskind E, et al. (2014) Extended-spectrum-beta-lactamase producing bacteria related urinary tract infection in renal transplant recipients and effect on allograft function. PLoS One 9: e91289. doi: 10.1371/journal.pone.0091289 PMID: 24637786

33. Pournaras S, Ikonomidou A, Kristo I, Tsakris A, Maniatis AN (2004) CTX-M enzymes are the most common extended-spectrum beta-lactamases among Escherichia coli in a tertiary Greek hospital. J Antimicrob Chemother 54: 574–575. PMID: 15215222

34. Mugnaioli C, Luzzaro F, De Luca F, Brigante G, Perilli M, et al. (2006) CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother 50: 2700–2706. PMID: 16870761

35. Machado E, Coque TM, Canton R, Novais A, Sousa JC, et al. (2007) High diversity of extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae from Portugal. J Antimicrob Chemother 60: 1370–1374. PMID: 17913717

36. Mendonca N, Leitao J, Managerio V, Ferreira E, Canica M (2007) Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrob Agents Chemother 51: 1946–1955. PMID: 17371815

37. Coque TM, Baquero F, Canton R (2008) Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 13.

38. Goyal A, Prasad KN, Prasad A, Gupta S, Ghoshal U, et al. (2009) Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res 129: 695–700. PMID: 19692752

39. Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, et al. (1995) SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 39: 899–905. PMID: 7785992

40. Rodriguez-Bano J, Navarro MD, Romero L, Muniaín MA, de Cueto M, et al. (2006) Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43: 1407–1414. PMID: 17083012